Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the next phase of development for its withZeta.ai platform, including the planned launches of ZetaSwarm(TM), an autonomous multi-agent AI research system, and ZetaOmics(TM), a computational biology and multi-omic analytics toolkit. The platform will also incorporate new enterprise-grade capabilities designed to support institutional oncology research and drug discovery workflows, according to a press release.
The withZeta.ai platform, described as a multi-agentic AI co-scientist, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company, which operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
Lantern Pharma is a clinical-stage precision oncology company that leverages AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The announcement highlights Lantern Pharma's commitment to advancing AI-driven drug discovery and expanding its platform capabilities. The new tools aim to accelerate research by providing autonomous multi-agent AI systems and comprehensive multi-omic analytics, which could significantly impact the efficiency of oncology research.
For more information, the full press release is available at https://ibn.fm/YpA7NA. Updates on Lantern Pharma can be found at https://ibn.fm/LTRN.
The company's AI platform, withZeta.ai, is part of a broader trend in the pharmaceutical industry to integrate artificial intelligence into drug development. By offering these tools as a subscription service, Lantern Pharma is positioning itself to generate recurring revenue while supporting the global biomedical research community.
InvestorWire, a specialized communications platform, syndicated the press release. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release syndication, social media distribution, and a full array of tailored corporate communications solutions.
